![Surviving-an-FDA-GCP-Inspection-500.jpg Surviving an FDA GCP Inspection](https://www.centerwatch.com/ext/resources/products/Surviving-an-FDA-GCP-Inspection-500.jpg?height=200&t=1605810958&width=200)
Home » The CenterWatch Weekly, August 07, 2017
The CenterWatch Weekly, August 07, 2017
August 7, 2017
Mega CROs still skyrocketing in M&A deals. But is the cycle winding down?
The CRO industry continues to undergo a wave of M&A activity with last week’s announcement by LabCorp that it is acquiring the privately owned CRO Chiltern International for $1.2 billion. “This acquisition strengthens our position as a leading life sciences company that delivers innovative diagnostics and drug development solutions to improve health and improve lives,” said David P. King, chairman and CEO of LabCorp, in a statement announcing the acquisition. “Our acquisition of Covance has demonstrated the value of combining diagnostic and CRO capabilities, expertise, data and leadership. The addition of Chiltern furthers our strategy and will provide us with enhanced capabilities across a broader client base as we continue to innovate and grow.”
BRANY protocol launch showcases paradigm shift in behavioral and social sciences research
Biomedical Research Alliance of New York (BRANY) released a new research protocol template specifically designed to address the unique needs of social-behavioral-educational researchers. This launch comes as part of Protocol Builder, a secure, cloud-based protocol writing application. This special template provides a guided, step-by-step protocol-writing process for investigators who specialize in psychology, nursing, education and other disciplines that are focused on behavioral and social functioning.
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.
Upcoming Events
-
21Oct